Partnerships: Bargaining Biotechs

Published on: 

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-04-01-2001, Volume 0, Issue 0

Uniondale, New York, USA-Thirty-eight companies submitted proposals to develop OSI-774, OSI Pharmaceuticals' lead cancer candidate, making it the most sought-after compound of 2000. The statistic was revealed with some satisfaction by Myrtle Potter, chief operating officer of Genentech, the joint winner-along with Roche, its majority stockholder-at the Economist Conferences' annual pharmaceuticals conference.